Access cutting-edge pheochromocytoma treatment through this clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.
Access pheochromocytoma specialists in Iowa City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pheochromocytoma treatment provided free
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutif
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this pheochromocytoma clinical trial in Iowa City, IA
If you're searching for pheochromocytoma treatment options in Iowa City, IA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Iowa City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pheochromocytoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.